Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Strida-funded research makes cancer target breakthrough
The new target gene is called methylenetetrahydrofolate reductase, or MTHFR. The McGill University Health Centre (MUHC) researchers were able to inhibit the function of the gene by creating
The new target gene is called methylenetetrahydrofolate reductase, or MTHFR. The McGill University Health Centre (MUHC) researchers were able to inhibit the function of the gene by creating
The study showed that the improvements in cardiovascular risk factors achieved with rimonabant 20mg/day at the end of the first year of treatment were maintained in the second
The first US Department of Defense (DoD) contract, for $2.5 million, will support the second year of Diversa’s program for rapid antibody-based biological countermeasures (RAbBC). The second contract,
The ascending-dose, placebo controlled trial will evaluate the safety as well as the pharmacokinetic and pharmacodynamic profile of DG041, DeCode’s novel, first-in-class, orally-administered small molecule. In preclinical studies,
The trial, named ASCOT, involved nearly 20,000 patients with high blood pressure, and was designed to compare the effects of a Norvasc-based regimen versus a standard beta-blocker based
In the first of the two studies, results showed that Merck/Schering-Plough’s Vytorin (ezetimibe/simvastatin) was better than Lipitor (atorvastatin calcium) at lowering LDL, or ‘bad’, cholesterol across the dosing
In this trial, vascular endothelial growth factor-2 (VEGF-2) in the form of ‘naked’ plasmid DNA was delivered in defined doses by direct injection into the heart muscle. Results
The study, part of Boehringer Ingelheim’s ongoing clinical development program to assess the therapeutic potential of pramipexole for the treatment of restless legs syndrome (RLS), demonstrated that a
Previous studies have demonstrated that tetrabenazine improves the symptoms associated with a number of hyperkinetic movement disorders, which include Huntington’s disease, other choreas and tardive dyskinesia. Clinical study
The revelation comes after The Dutch Association of Insurers instructed its members, which include major internationals Aegon NV and ING Groep NV, to draw up policies that cater